Immunohistochemical detection of H-ras protooncoprotein p21 indicates favorable prognosis in node-negative breast cancer patients

Tumor Biology

Volumn 20, Issue 4, 1999, Pages 173-183

  Göhring, Uwe Jochen ^a   Schöndorf, Thomas ^b   Kiecker, Volker R ^b   Becker, Martina ^b   Kurbacher, Christian ^b   Scharl, Anton ^b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b NONE

Author keywords

Breast cancer; H ras p21; Immunohistochemistry; Prognosis; Prognostic factor

Indexed keywords

CYCLINE; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; PROTEIN ANTIBODY; PROTEIN P21; STEROID RECEPTOR; TAMOXIFEN;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR VOLUME;

EID: 0344759138     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000030061     Document Type: Article

References (38)

1. Leslie KO, Howard P: Oncogenes and antioncogenes in human breast carcinoma. Pathol Annu 1992;27: 321-342.
2. Field JK, Spandidos DA: The role of ras and myc oncogenes in human solid tumors and their relevance in diagnosis and prognosis. Anticancer Res 1990;10:1-22.
3. Haubruck H, McCormick F: Ras p21: Effects and regulation. Biochim Biophys Acta 1991;1072:215-229.
4. McCormick F: Activators and effectors of ras p21 proteins. Curr Opin Genet Dev 1994;4:71-76.
5. Chen CY, Faller DV: Direction of p21 ras-generated signals towards cell growth or apoptosis is determined by protein kinase C and Bcl-2. Oncogene 1995;11:1487-1498.
6. Chambers AF, Tuck AB: Ras-responsive genes and tumor metastasis. Crit Rev Oncog 1993;4:95-114.
7. Agnatis NJ, Parissi P, Anagnostakis D, Spandidos DA: Comparative study of Harvey-ras oncogene expression with conventional clinicopathologic parameters of breast cancer. Oncology 1986;43:36-39.
8. Köster A, Landgraf S, Leipold A, et al: Expression of oncogenes in human breast cancer specimens. Anticancer Res 1991;11:193-201.
9. Spandidos DA, Agnatis NJ: Human malignant tumours of the breast, as compared to their normal tissue, have elevated expression of the Harvey ras oncogene. Anticancer Res 1984;4:269-272.
10. Whittaker JL, Walker RA, Varley JM: Differential expression of cellular oncogenes in benign and malignant human breast tissue. Int J Cancer 1986;38:651-655.
11. Clair T, Miller W, Cho-Chung Y: Prognostic significance of the expression of the ras protein with a molecular weight of 21000 by human breast cancer. Cancer Res 1987;47:5290-5293.
12. Tanaka T, Slamon DJ, Battifora H, Cline MJ: Expression of p21ras oncoproteins in human cancers. Cancer Res 1986;46:1465-1470.
13. Watson DMA, Elton RA, Jack WJL, Dixon JM, Chetty U, Miller WR: The H-ras oncogene product p21 and prognosis in human breast cancer. Breast Cancer Res Treat 1990; 17:161-169.
14. De Biasi F, Del Sal G, Horan-Hand P: Evidence of enhancement of the rat oncogene protein product (p21) in a spectrum of human cancers. Int J Cancer 1989;43:431-435.
15. Horan-Hand P, Thor A, Wienderlich D, Muravo R, Caruso A, Scholm J: Monoclonal antibodies of predefined specificity detects activated ras gene expression in human mammary and colon carcinoma. Proc Natl Acad Sci USA 1984;81: 5227-5231.
16. Agnatis NJ, Petraki C, Markulatos P, Spandidos DA: Immunohistochemical study of the ras oncogene expression in human breast lesions. Anticancer Res 1986;6:1157-1160.
17. Candlish W, Kerr IB, Simpson HW: Immunocytochemical demonstration and significance of p21 ras family oncogene product in benign and malignant breast disease. J Pathol 1986;150:163-167.
18. Going JJ, Anderson TJ, Wyllie AH: Ras p21 in breast tissue: Associations with pathology and cellular localisation. Br J Cancer 1992;65:45-50.
19. Ohuchi N, Thor A, Page DI, Horan-Hand P, Halter S, Schlom J: Expression of the 21,000 molecular weight ras protein in a spectrum of benign and malignant human mammary tissues. Cancer Res 1986;46:2511-2519.
20. Walker RA, Wilkinson N: P21 ras protein expression in benign and malignant human breast. J Pathol 1988;156:147-153.
21. Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 1990;61:759-767.
22. Göhring U-J, Scharl A, Stoffl M, Ahr A, Becker M, Crombach G: Der Nachweis des Proliferating Cell Nuclear Antigen (PCNA) im primä ren Mammakarzinom - ein Proliferationsmarker als Prognosefaktor bei nodal-positiven Patientinnen. Tumordiagn Ther 1994;15:171-175.
23. Scharl A, Vierbuchen M, Würz H: Immunohistochemischer Nachweis von Östrogen- und Progesteronrezeptoren beim Mammakarzinom mit Hilfe monoklonaler Antikörper: Vergleich mit der biochemischen Rezeptoranalyse. Pathologe 1989; 10:31-38.
24. Hsu S-M, Raisse L, Fanger H: Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques. J Histochem Cytochem 1981;29:577-580.
25. Peto R, Pike MC, Armitage P: Design and analyses of randomised clinical trials requiring prolonged observation of each patient. Br J Cancer 1977;35:1-39.
26. Cox DR: Regression models and life-tables. J R Stat Soc 1972;34: 187-200.
27. Gutheil JC, Anderson TJ, Kapil V, Needleman SW: Immunoprecipitation of cell lysates with RAP-5 does not specifically detect ras oncogen product p21. Hum Pathol 1989; 130: 1176.
28. Biunno I, Pozzi MR, Pierotti MA, Pilotti S, Cattoretti G, Della-Porta G: Structure and expression of oncogenes in surgical specimens of human breast carcinomas. Br J Cancer 1988;57:464-468.
29. Corell B, Zoll B: Comparison between the allelic frequency distribution of the Ha-ras 1 locus in normal individuals and patients with lymphoma, breast and ovarian cancer. Hum Genet 1988;79:255-259.
30. Rochlitz CF, Scott GK, Dodson JM, Liu E, Dollbaum C, Smith HS, Benz CC: Incidence of activating ras oncogene mutations associated with primary and metastatic human breast cancer. Cancer Res 1989;49: 357-360.
31. Theillet C, Linderau R, Escot C: Loss of c-Ha-ras allele and aggressive human primary breast carcinomas. Cancer Res 1986;46:4776-4781.
32. Spandidos DA, Wilkie NW: The normal human H-ras-1 gene can act as an oncosuppressor. Br J Cancer Suppl 1988;53:67-71.
33. Noda M, Ko N, Ogura A, Liu D-G, Amano T, Ikawa Y: Sarcoma viruses carrying ras oncogenes induce differentiation-associated properties in neural cell line. Nature 1985;318: 73-75.
34. Hirakawa T, Ruley HE: Rescue of cells from ras oncogene induced growth arrest by second, complementing oncogene. Proc Natl Acad Sci USA 1988;85:1519.
35. Ridley AJ, Paterson HF, Noble M, Land H: ras mediated cell cycle arrest is altered by nuclear oncogenes to induce Schwann cell transformation. EMBOJ 1988;7:1635.
36. Wynford-Thomas D, Bond JA, Wyllie FS, et al: Conditional immortisation of human thyroid epithelial cells: A tool for analysis of oncogene action. Mol Cell Biol 1990; 10: L5365.
37. Abrams SI, Hand PH, Tsang KY, Schlom J: Mutant ras epitopes as targets for cancer vaccines. Semin Oncol 1996;23:118-134.
38. De Vries JE, ten Kate J, Bosnian FT: p21ras in carcinogen. Pathol Res Pract 1996;192:658-668.